Lvnan T. Yan
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Impact of low preoperative appendicular skeletal muscle mass on postoperative complications and short-term outcomes in liver transplant recipients: a propensity score-matched retrospective study.
Journal: Frontiers in surgery
Published: July 23, 2025
The Age-Male-Albumin-Bilirubin-Platelet Risk Score Predicts Postoperative Prognosis of Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Study.
Journal: The Journal of surgical research
Published: October 07, 2024
Long-Term Outcome of Repeat Resection versus Radiofrequency Ablation for Intrahepatic Recurrence after Curative Resection of Hepatocellular Carcinoma Initially within Barcelona Clinic Liver Cancer Staging System 0-A Stages: A Multicenter Study.
Journal: Digestive diseases (Basel, Switzerland)
Published: August 25, 2024
A new clinical classification of congenital biliary dilatation - HUAXI CBD classification.
Journal: BMC pediatrics
Published: May 15, 2024
Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: January 11, 2024
Epstein-Barr virus positive diffuse large B-cell lymphoma complicated with plasma cell myeloma: report of a case
Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology
Published: June 01, 2023
HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma.
Journal: Redox biology
Published: October 05, 2022
The lipid transporter HDLBP promotes hepatocellular carcinoma metastasis through BRAF-dependent epithelial-mesenchymal transition.
Journal: Cancer letters
Published: July 26, 2022
Oxygen-carrying sequential preservation mitigates liver grafts ischemia-reperfusion injury.
Journal: iScience
Published: July 18, 2022
HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.
Journal: Cellular and molecular gastroenterology and hepatology
Published: July 11, 2022
A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients.
Journal: Frontiers in immunology
Published: July 10, 2022
Last Updated: 09/26/2026